Stryker Corp

Explore how an Iranian‑linked cyberattack on Stryker Corp disrupted its global operations, impacted supply chains, and what it means for investors and patient safety.

Institutional trading shows mixed sentiment for Stryker Corp. while big investors like Penobscot add shares, confident in its R&D‑driven growth and global reach.

Discover why institutional investors and analysts are bullish on Stryker Corp, the $135 billion medical‑device leader, after its Q4 2025 earnings beat and upgraded price targets.

Stryker Corporation has launched its next-generation InThrill Thrombectomy System, a medical device designed to improve treatment of small vessel and arteriovenous thrombosis.

Stryker Corp has secured FDA clearance for its OptaBlate BVN System, bolstering its market position and maintaining its strong valuation in the medical technology industry.